Position in NVS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$51,717
-$368,037 QoQ
Shares Held
330
-88.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
#1,424
of 1,598 holders
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Ascentis Independent Advisors holds $465,945 across 9 Drug Manufacturers - General names. NVS ranks #3 (11.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
778 | $195,769 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
703 | $88,811 | |
| 3 | NVS |
Novartis AG
This page
|
330 | $51,717 | |
| 4 | JNJ |
Johnson & Johnson
|
175 | $44,443 | |
| 5 | MRK |
Merck & Co., Inc.
|
300 | $38,549 | |
| 6 | GSK |
GSK plc
|
697 | $36,536 | |
| 7 | SNY |
Sanofi
|
144 | $6,143 | |
| 8 | LLY |
ELI LILLY & Co
|
3 | $3,598 |
All Filings in NVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $51,717 | 330 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $419,754 | 2,748 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $206,529 | 1,498 | Shares | Sole | 2026-01-29 | |
| 2024-09-30 | $39,563 | 344 | Shares | Sole | 2024-10-29 | |
| No filing history on record for this holder in this stock. | ||||||